News and Stories About immunotherapy
Meet a Research Grantee: Daria Esterházy, PhD
Editor’s note: We recently announced the recipients of the Pancreatic Cancer Action Network’s (PanCAN) 2020 research grants. Now we’d like […]
READ MORE
Meet a Research Grantee: Xiaoyang Qi, PhD
Editor’s note: We recently announced the recipients of the Pancreatic Cancer Action Network’s (PanCAN) 2020 research grants. Now we’d like […]
READ MORE
Things to Know About Immunotherapy Clinical Trials
Editor’s note: “Jeopardy!” host Alex Trebek and former Sen. Harry Reid have publicly mentioned being treated with an experimental immunotherapy […]
READ MORE
Keytruda Use Expanded for Pancreatic Cancer Patients
A drug that received unprecedented approval in the U.S. three years ago is now available for even more patients. In […]
READ MORE
Research Grantees Stay Connected During Coronavirus Pandemic
Editor’s note: May is National Cancer Research Month, which provides an opportunity to highlight the incredible scientific and clinical research […]
READ MORE
Grantees Explore New Treatment Combination
All the way across the country from one another, two pancreatic cancer researchers made similar discoveries in their labs. Rushika […]
READ MORE
Treatments Based on Patient Biology
About one in four pancreatic cancer patients have changes in their tumor that suggest certain treatments may work particularly well […]
READ MORE
How Know Your Tumor Has Helped These Survivors
A recent paper published in the prestigious journal Lancet Oncology showed that the Pancreatic Cancer Action Network’s (PanCAN) Know Your […]
READ MORE
Molecular Profiling Gave Patient More Options
Stage IV pancreatic cancer survivor Ken Harding was no longer having great results after nine months on standard chemotherapy. But […]
READ MORE
2019 Year in Review: Progress in Research
Editor’s note: This article kicks off our 2019 Year in Review series – highlighting the research advancements that you – […]
READ MORE
Pancreatic Cancer Immunotherapy Clues Revealed
When immunology expert Ingunn Stromnes, PhD, assistant professor of microbiology and immunology at the University of Minnesota, unexpectedly discovered a […]
READ MORE
Bacteria May Impact Pancreatic Cancer Survival
A new study out today in Cell links tumor bacteria to long-term pancreatic cancer survival. Examining tumor samples from pancreatic […]
READ MORE
What Is Cancer Immunotherapy?
Cancer immunotherapy involves empowering the patient’s immune system to recognize, attack and destroy cancer cells. While remarkable results have been […]
READ MORE
PanCAN Leader ‘Blown Away’ by Cancer Conference
“I’ve been attending the American Association for Cancer Research (AACR) annual meetings for several years, and this year’s conference was […]
READ MORE
Cancer Immunotherapy Pioneers Win Nobel Prize in Physiology or Medicine
The 2018 Nobel Prize in Physiology or Medicine has been awarded to James (Jim) Allison, PhD, and Tasuku Honjo, MD, […]
READ MORE
Persistence, Precision Medicine Pay off for Pancreatic Cancer Patient
When doctors told David Watson of Santa Monica, Calif., that he had type 2 diabetes in November 2016, he couldn’t […]
READ MORE
Meet Our 2018 Research Grantees: Translational Awards
This year, the Pancreatic Cancer Action Network (PanCAN) awarded eight prestigious research grants to scientists and clinicians in the United […]
READ MORE
New Research Suggests Age May Benefit Response to Immunotherapy
Cancer immunotherapy involves efforts to harness the patient’s own immune system to recognize and attack tumor cells. To date, the […]
READ MORE
Grantee Discusses Immunotherapy in Smithsonian Magazine
Pancreatic Cancer Action Network (PanCAN) grantee Dung Le, MD, provided commentary in the April 2018 issue of Smithsonian Magazine. The […]
READ MORE
Grantee’s Study Suggests Bacteria Can Influence Tumor Growth and Immune Response
Scientists have known for quite some time that pancreatic tumors are surrounded by an especially dense and complex “stroma,” a […]
READ MORE
2017 Year in Review: Top 10 News Stories
Editor’s note: This article is another installment in our “Year in Review” series recapping the year’s top stories in pancreatic […]
READ MORE
Research Team’s Work Provides Clues that Explain Long-term Survival
A multi-institutional research team, including Vinod Balachandran, MD, and Steven Leach, MD, set out to ask an important question: “What […]
READ MORE
Discovery Channel Clinical Trials Series: Episode 2 – “Treatment”
The second episode of the three-part Discovery documentary on clinical trials, First in Human, follows the gripping story of three […]
READ MORE
New Findings Explain How Immune Cells Support Pancreatic Tumors
A Pancreatic Cancer Action Network Career Development Award in 2014 allowed David DeNardo, PhD, to ask and answer important questions […]
READ MORE
The Road to Effective Immunotherapy for Pancreatic Cancer Patients
Last week, we shared the exciting news that an immunotherapy agent, Keytruda, was the first drug approved by the FDA […]
READ MORE
Unprecedented Drug Approval Can Benefit Pancreatic Cancer Patients
For the first time, the U.S. Food and Drug Administration (FDA) has approved a cancer drug based only on molecular […]
READ MORE
Studying How a New Immunotherapy Works in Each Patient
Thanks to the generosity of donors, we awarded our largest-ever grant of $2 million in 2016 to accelerate a large-scale […]
READ MORE
A New Strategy to Allow Immune Attack of Pancreatic Tumors
The more researchers analyze the interaction between pancreatic cancer cells and the patient’s immune system, the more complex the relationship […]
READ MORE
Your Advocacy in Action: New Federal Research Funding to Explore Pancreatic Cancer Immunotherapy
Together, we have been relentless in fighting for increased funding for pancreatic cancer research and today, we are proud to […]
READ MORE
Grantee’s Preclinical Immunotherapy Data Shows Promise
Pancreatic cancer recently moved from the fourth to the third leading cause of cancer-related death in the United States, and […]
READ MORE
Grantee’s Early-Phase Immunotherapy Clinical Trial Shows Encouraging Results
Preliminary results from an early-phase immunotherapy clinical trial suggest that an innovative treatment could be effective for patients with locally-advanced or borderline-resectable pancreatic cancer.
